43 results on '"Balogh, Karla"'
Search Results
2. Immune Responses in Oral Papillomavirus Clearance in the MmuPV1 Mouse Model
3. Passive Immunization with a Single Monoclonal Neutralizing Antibody Protects against Cutaneous and Mucosal Mouse Papillomavirus Infections
4. Depo Medroxyprogesterone (DMPA) Promotes Papillomavirus Infections but Does Not Accelerate Disease Progression in the Anogenital Tract of a Mouse Model
5. A Comparative Study on Delivery of Externally Attached DNA by Papillomavirus VLPs and Pseudoviruses
6. Mouse Papillomavirus L1 and L2 Are Dispensable for Viral Infection and Persistence at Both Cutaneous and Mucosal Tissues
7. Humans with inherited T cell CD28 deficiency are susceptible to skin papillomaviruses but are otherwise healthy
8. The environmental pollutant and tobacco smoke constituent dibenzo[def,p]chrysene is a co-factor for malignant progression of mouse oral papillomavirus infections
9. Antibody-Mediated Immune Subset Depletion Modulates the Immune Response in a Rabbit (Oryctolagus cuniculus) Model of Epstein-Barr Virus Infection
10. Abstract LB-200: A cGMP-grade chimeric papillomavirus candidate vaccine (HPV16 RG1-VLP) confers long term cross-protection compared to a nonavalent hpv vaccine in a pre-clinical papillomavirus animal model
11. Abstract LB-200: A cGMP-grade chimeric papillomavirus candidate vaccine (HPV16 RG1-VLP) confers long term cross-protection compared to a nonavalent hpv vaccine in a pre-clinical papillomavirus animal model
12. Papillomavirus can be transmitted through the blood and produce infections in blood recipients: Evidence from two animal models
13. Papillomavirus can be transmitted through the blood and produce infections in blood recipients: Evidence from two animal models
14. BET bromodomain inhibitors show anti-papillomavirus activity in vitro and block CRPV wart growth in vivo
15. Mouse papillomavirus infection persists in mucosal tissues of an immunocompetent mouse strain and progresses to cancer
16. Mouse papillomavirus infections spread to cutaneous sites with progression to malignancy
17. The Mouse Papillomavirus Infection Model
18. Broad Cross-Protection Is Induced in Preclinical Models by a Human Papillomavirus Vaccine Composed of L1/L2 Chimeric Virus-Like Particles
19. Mouse papillomavirus MmuPV1 infects oral mucosa and preferentially targets the base of the tongue
20. Tracking vaginal, anal and oral infection in a mouse papillomavirus infection model
21. Durable immunity to oncogenic human papillomaviruses elicited by adjuvanted recombinant Adeno-associated virus-like particle immunogen displaying L2 17–36 epitopes
22. A Novel Pre-Clinical Murine Model to Study the Life Cycle and Progression of Cervical and Anal Papillomavirus Infections
23. Antibody detection in tear samples as a surrogate to monitor host immunity against papillomavirus infections in vaccinated and naturally infected hosts
24. Formulation of cidofovir improves the anti-papillomaviral activity of topical treatments in the CRPV/rabbit model
25. Long-peptide therapeutic vaccination against CRPV-induced papillomas in HLA-A2.1 transgenic rabbits
26. Secondary Infections, Expanded Tissue Tropism, and Evidence for Malignant Potential in Immunocompromised Mice Infected with Mus musculus Papillomavirus 1 DNA and Virus
27. Synonymous codon changes in the oncogenes of the cottontail rabbit papillomavirus lead to increased oncogenicity and immunogenicity of the virus
28. Vaccine generated immunity targets an HPV16 E7 HLA-A2.1-restricted CD8+ T cell epitope relocated to an early gene or a late gene of the cottontail rabbit papillomavirus (CRPV) genome in HLA-A2.1 transgenic rabbits
29. Mucosally delivered peptides prime strong immunity in HLA-A2.1 transgenic rabbits
30. Differences in methodology, but not differences in viral strain, account for variable experimental outcomes in laboratories utilizing the cottontail rabbit papillomavirus model
31. Using HLA-A2.1 Transgenic Rabbit Model to Screen and Characterize New HLA-A2.1 Restricted Epitope DNA Vaccines
32. Papillomavirus DNA complementation in vivo
33. Strong and Specific Protective and Therapeutic Immunity Induced by Single HLA-A2.1 Restricted Epitope DNA Vaccine in Rabbits
34. CRPV Genomes with Synonymous Codon Optimizations in the CRPV E7 Gene Show Phenotypic Differences in Growth and Altered Immunity upon E7 Vaccination
35. Wounding prior to challenge substantially improves infectivity of cottontail rabbit papillomavirus and allows for standardization of infection
36. Protective immunity with an E1 multivalent epitope DNA vaccine against cottontail rabbit papillomavirus (CRPV) infection in an HLA-A2.1 transgenic rabbit model
37. Detection of L1, infectious virions and anti-L1 antibody in domestic rabbits infected with cottontail rabbit papillomavirus
38. Establishment of a Cottontail Rabbit Papillomavirus/HLA-A2.1 Transgenic Rabbit Model
39. Complete Protective Immunity induced by Cottontail Rabbit Papillomavirus E1 Epitope DNA Vaccination in HLA-A2.1 transgenic rabbits (47.13)
40. Impact of genetic changes to the CRPV genome and their application to the study of pathogenesis in vivo
41. Preclinical Model To Test Human Papillomavirus Virus (HPV) Capsid Vaccines In Vivo Using Infectious HPV/Cottontail Rabbit Papillomavirus Chimeric Papillomavirus Particles
42. Papillomavirus Particles Assembled in 293TT Cells Are Infectious In Vivo
43. Treatment of latent rabbit and human papillomavirus infections with 9-(2-phosphonylmethoxy)ethylguanine (PMEG)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.